A successful pitch must have a clear investment thesis, which explains the technology, its application, and its need.

Our latest Voices of Biotech podcast series highlighted a myriad of challenges, triumphs, and solutions surrounding sustainability in our industry. One core theme that prevailed across the episodes referred to the need for the whole ecosystem to work together to tackle sustainability effectively.

Experts at BIO said to become a partner of choice there is a need for early-stage biotech companies to stand out in a crowded field.

BIO-Europe Spring 2023's therapeutic focus this year is on the latest innovation in oncology and neurology. Leading international life science venture capital firm TVM Capital Life Sciences has multiple investments in these areas. The firm continues to build its portfolio with new investments from its Life Science Innovation II fund.

Despite the general negativity, there are two investment sectors for China biopharma that are very positive: Out-bound cross-border pharmaceutical partner deals and the large amount of funds raised by prominent China biopharma venture capital firms.

At BIO-Europe 2023, pre-clinical, clinical and commercial stage biotech showcased their science, which included next-gen antisense oligonucleotide (ASO) therapies, immunotherapy platform technology, T-cells for solid tumors, ADCs based on the payload amanitin in oncology and targeted antigen-specific immunotherapies for severe autoimmune diseases.